Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02987387 · ClinicalTrials.gov registry record
COMPASSION XT PAS - Post-approval Study of the SAPIEN XT THV in Patients With Pulmonary Valve Dysfunction
A clinical trial, sponsored by Edwards Lifesciences.
- Completed
- Registry status
- 57
- Enrollment target
NCT02987387 is a clinical trial that has completed, run by Edwards Lifesciences. The registered enrollment target is 57 participants.
The verdict
NCT02987387 has completed, sponsored by Edwards Lifesciences.
- COMPLETED
- Registry status
- 57 participants
- Enrollment target
Study Summary
This study will confirm the safety and effectiveness of the Edwards Lifesciences SAPIEN XT Transcatheter Heart Valve (THV) System in patients with a dysfunctional right ventricular outflow tract (RVOT) conduit with a clinical indication for intervention in a post-market setting.
Interventions
- DEVICE SAPIEN XT THV
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 57 participants |
| Start Date | 2017-07-17 |
| Est. Completion | 2025-09-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02987387
The ClinicalTrials.gov registry entry for NCT02987387 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 57 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Edwards Lifesciences, which has 57 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which SAPIEN XT THV is the first listed.
NCT02987387 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02987387 about?
NCT02987387 is a clinical study titled "COMPASSION XT PAS - Post-approval Study of the SAPIEN XT THV in Patients With Pulmonary Valve Dysfunction". This study will confirm the safety and effectiveness of the Edwards Lifesciences SAPIEN XT Transcatheter Heart Valve (THV) System in patients with a dysfunctional right ventricular outflow tract (RVOT) conduit with a clinical indication for intervention in a post-market setting.
What is the current status of trial NCT02987387?
This trial is currently completed. The enrollment target is 57 participants. The study started on 2017-07-17. Estimated completion is 2025-09-30.
What interventions are being tested in trial NCT02987387?
The interventions under investigation include: SAPIEN XT THV (DEVICE).
Who is sponsoring clinical trial NCT02987387?
This trial is sponsored by Edwards Lifesciences, which has 57 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.